Familial dilated cardiomyopathy in a child: a case report

Ali Ismail,Dima Khreis,Amani Assaad,Marianne Nimah Majdalani
DOI: https://doi.org/10.1186/s12887-024-04614-4
2024-04-01
BMC Pediatrics
Abstract:Abstract Background Dilated cardiomyopathy (DCM) commonly leads to heart failure (HF) and represents the most common indication for cardiac transplantation in the pediatric population. Clinical manifestations of DCM are mainly the symptoms of heart failure; it is diagnosed by EKG, chest x-ray and echocardiography. For the idiopathic and familial diseases cases of DCM, there are no definite guidelines for treatment in children as they are treated for prognostic improvement. Case presentation We report the case of a 2-year-old girl diagnosed with dilated cardiomyopathy associated with homozygous mutation in the Myosin Light Chain 3 gene admitted for edema in lower extremities, muscle weakness, lethargy and vomiting, and she was found to be in cardiogenic shock. Chest x-ray showed cardiomegaly and EKG showed first degree atrioventricular block. Echocardiogram showed severe biventricular systolic and diastolic dysfunction. After 70 days of hospitalization, the patient went into cardiac arrest with cessation of electrical and mechanical activity of the heart, despite cardiopulmonary resuscitative efforts. Conclusion Although rare, pediatric DCM carries a high risk of morbidity and mortality and a lack of curative therapy.
pediatrics
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the clinical manifestations, diagnosis, and treatment plans of childhood Familial Dilated Cardiomyopathy (FDCM), especially for cases carrying specific gene mutations (such as homologous mutations in the MYL3 gene). Through a specific case, that of a 2 - year - old girl who has FDCM due to carrying a homologous mutation in the MYL3 gene, the paper describes in detail the development of her condition, the treatment process, and her final unfortunate death. In addition, the paper also discusses the limitations of current treatment methods for FDCM and possible future research directions, especially the progress in genetics and targeted therapy. ### Background and Problem of the Paper Dilated Cardiomyopathy (DCM) is a myocardial disease that leads to left ventricular or biventricular dilation and systolic dysfunction, usually without a clear cardiovascular cause (such as coronary artery disease, hypertension, valvular disease, or congenital heart disease). In the pediatric population, DCM is a serious heart disease that often leads to heart failure and is one of the main indications for heart transplantation. Despite advances in medical technology, about 40% of children with DCM require heart transplantation or die within two years after diagnosis. ### Research Objectives 1. **Describe specific cases**: By describing the case of a 2 - year - old girl, show the clinical manifestations, diagnostic methods, and treatment process of FDCM. 2. **Explore the impact of gene mutations**: Analyze the role of homologous mutations in the MYL3 gene in the pathogenesis of FDCM and discuss their impact on treatment. 3. **Evaluate the effectiveness of existing treatment plans**: Summarize the drugs and methods currently used to treat FDCM and evaluate their effectiveness in pediatric patients. 4. **Propose future research directions**: Point out the problems that need further research in genetics and targeted therapy to improve the prognosis of FDCM patients. ### Main Findings - **Clinical manifestations**: The child showed symptoms of heart failure, such as edema, muscle weakness, lethargy, and vomiting, and was in a cardiogenic shock state upon admission. - **Diagnostic methods**: DCM was diagnosed by electrocardiogram (EKG), chest X - ray, and echocardiogram, showing severe biventricular systolic and diastolic dysfunction. - **Treatment process**: Although multiple drugs (such as diuretics, ACE inhibitors, β - receptor blockers, etc.) were used and multiple Levosimendan infusions were carried out, the child's condition still gradually deteriorated and finally died due to cardiac arrest. - **Gene mutation**: Through whole - exome sequencing, it was found that the child carried a homologous mutation in the MYL3 gene, which is related to Familial Dilated Cardiomyopathy, but its specific pathogenic mechanism is not yet fully understood. ### Conclusions - Childhood FDCM is a high - risk disease, and currently there is a lack of clear treatment guidelines. Most treatment plans are based on adult studies. - Although progress has been made in genetic research, further research is still needed in gene - targeted therapy. - More multidisciplinary cooperation and individualized treatment strategies are required to improve the survival rate and quality of life of children with FDCM. ### Future Research Directions - **Genetic research**: Further explore the specific mechanism of the MYL3 gene mutation in FDCM. - **Targeted therapy**: Develop targeted therapeutic drugs for specific gene mutations to improve the prognosis of patients. - **Multidisciplinary cooperation**: Strengthen the cooperation among cardiovascular, genetics, critical care medicine, and other disciplines to develop more effective treatment plans. Through these studies, it is hoped that more effective treatment and support can be provided for children with FDCM in future clinical practice.